BACKGROUND:Nonsuicidal self-injury (NSSI) is common in adolescents and young adults, and few evidence-based treatments are available for this significant problem. N-acetylcysteine (NAC) is a widely available nutritional supplement that has been studied in some psychiatric disorders relevant to NSSI including mood and addictive disorders. This pilot study tested the use of NAC as a potential treatment for NSSI in youth. METHODS:Thirty-five female adolescents and young adults with NSSI aged 13-21 years were enrolled in this study that had an open-label, single-arm study design. All participants were given oral NAC as follows: 600 mg twice daily (weeks 1-2), 1200 mg twice daily (weeks 3-4), and 1800 mg twice daily (weeks 5-8). Patients were seen every 2 weeks throughout the trial, at which time youth reported the frequency of NSSI episodes. Levels of depression, impulsivity, and global psychopathology were measured at baseline and at the end of the trial using the Beck Depression Inventory-II (BDI-II), Barratt Impulsivity Scale, and Symptoms Checklist-90 (SCL-90). RESULTS: About two-thirds of the enrolled female youth completed the trial (24/35). NAC was generally well tolerated in this sample. NAC treatment was associated with a significant decrease in NSSI frequency at visit 6 and visit 8 compared to baseline. We also found that depression scores and global psychopathology scores (but not impulsivity scores) decreased after NAC treatment. Decrease in NSSI was not correlated with decrease in BDI-II or SCL-90 scores, suggesting these might be independent effects. CONCLUSION: We provide preliminary evidence that NAC may have promise as a potential treatment option for adolescents with NSSI. The current results require follow-up with a randomized, placebo-controlled trial to confirm efficacy.
RCT Entities:
BACKGROUND: Nonsuicidal self-injury (NSSI) is common in adolescents and young adults, and few evidence-based treatments are available for this significant problem. N-acetylcysteine (NAC) is a widely available nutritional supplement that has been studied in some psychiatric disorders relevant to NSSI including mood and addictive disorders. This pilot study tested the use of NAC as a potential treatment for NSSI in youth. METHODS: Thirty-five female adolescents and young adults with NSSI aged 13-21 years were enrolled in this study that had an open-label, single-arm study design. All participants were given oral NAC as follows: 600 mg twice daily (weeks 1-2), 1200 mg twice daily (weeks 3-4), and 1800 mg twice daily (weeks 5-8). Patients were seen every 2 weeks throughout the trial, at which time youth reported the frequency of NSSI episodes. Levels of depression, impulsivity, and global psychopathology were measured at baseline and at the end of the trial using the Beck Depression Inventory-II (BDI-II), Barratt Impulsivity Scale, and Symptoms Checklist-90 (SCL-90). RESULTS: About two-thirds of the enrolled female youth completed the trial (24/35). NAC was generally well tolerated in this sample. NAC treatment was associated with a significant decrease in NSSI frequency at visit 6 and visit 8 compared to baseline. We also found that depression scores and global psychopathology scores (but not impulsivity scores) decreased after NAC treatment. Decrease in NSSI was not correlated with decrease in BDI-II or SCL-90 scores, suggesting these might be independent effects. CONCLUSION: We provide preliminary evidence that NAC may have promise as a potential treatment option for adolescents with NSSI. The current results require follow-up with a randomized, placebo-controlled trial to confirm efficacy.
Authors: J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Katja Weimer; Marco D Gulewitsch; Angelika A Schlarb; Juliane Schwille-Kiuntke; Sibylle Klosterhalfen; Paul Enck Journal: Pediatr Res Date: 2013-04-18 Impact factor: 3.756
Authors: Maya Katz; Seok Joon Won; Youngja Park; Adrienne Orr; Dean P Jones; Raymond A Swanson; Graham A Glass Journal: Parkinsonism Relat Disord Date: 2015-02-28 Impact factor: 4.891
Authors: Jennifer J Muehlenkamp; Laurence Claes; Lindsey Havertape; Paul L Plener Journal: Child Adolesc Psychiatry Ment Health Date: 2012-03-30 Impact factor: 3.033
Authors: Melinda Westlund Schreiner; Bryon A Mueller; Bonnie Klimes-Dougan; Erin D Begnel; Mark Fiecas; Dawson Hill; Kelvin O Lim; Kathryn R Cullen Journal: Front Psychiatry Date: 2020-01-24 Impact factor: 4.157
Authors: Siddhee A Sahasrabudhe; Thanharat Silamongkol; Young Woo Park; Alanna Colette; Lynn E Eberly; Bonnie Klimes-Dougan; Lisa D Coles; James C Cloyd; Gülin Öz; Bryon A Mueller; Reena V Kartha; Kathryn R Cullen Journal: J Psychiatr Brain Sci Date: 2021-04-29